OR WAIT null SECS
Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending September 10, 2022.
In the prospective, non-interventional SUSTAIN study, patients with active psoriatic arthritis received ustekinumab for 3 years in routine clinical care.
Rheumatology Network's month in review spotlights the most popular content from the past month.
“Whether treatment with litifilimab, a humanized monoclonal antibody against BDCA2, would be efficacious in reducing disease activity in patients with cutaneous lupus erythematosus has not been extensively studied.”
"Lupus nephritis (LN) patients might suffer from mental disorders which further prolong the LN treatment duration and affect patients' quality of life.”
“Kinesiophobia plays a major role in the onset, persistence, and exacerbation of chronic disability in a variety of musculoskeletal disorders."